Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

XBiotech Inc

Healthcare US XBIT

2.37USD
0.00(0%)

Last update at 2026-06-05T20:00:00Z

Day Range

2.352.38
LowHigh

52 Week Range

3.519.96
LowHigh

Fundamentals

  • Previous Close 2.37
  • Market Cap254.93M
  • Volume33097
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-35.76600M
  • Revenue TTM0.30M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 3.36M
  • Diluted EPS TTM-1.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -33.58800M -25.45800M -12.82700M 718.45M -21.13800M
Minority interest - - - - -
Net income -32.90000M -17.41400M -11.22100M 668.63M -21.13800M
Selling general administrative 6.30M 9.39M 18.20M 7.14M 5.27M
Selling and marketing expenses - - - - -
Gross profit 3.36M 12.57M 9.45M - 0.00000M
Reconciled depreciation 2.61M 2.65M 2.24M 2.36M 2.43M
Ebit -34.49000M -25.08200M -18.27600M -31.23300M -20.44600M
Ebitda -29.07600M -21.72300M -19.53400M -27.98400M -18.01300M
Depreciation and amortization 5.41M 3.36M -1.25800M 3.25M 2.43M
Non operating income net other 0.90M -0.37600M 5.45M 749.69M -0.14400M
Operating income -34.49000M -25.08200M -18.27600M -31.23300M -20.99400M
Other operating expenses 38.50M 43.48M 62.27M 31.23M 20.99M
Interest expense -0.90200M 1.09M 8.95M 748.80M 0.00000M
Tax provision -0.68800M -8.04400M -1.60600M 49.82M -
Interest income 3.82M 0.47M 2.46M 0.56M 0.40M
Net interest income 3.82M 0.47M 2.46M 0.56M 0.40M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.68800M -8.04400M -1.60600M 49.82M -0.14400M
Total revenue 4.01M 18.39M 44.00M 0.00000M 0.00000M
Total operating expenses 37.85M 37.66M 27.73M 31.23M 20.99M
Cost of revenue 0.65M 5.82M 34.55M - 0.00000M
Total other income expense net 0.90M -0.37600M 5.45M 749.69M -0.54400M
Discontinued operations - - - - -
Net income from continuing ops -32.90000M -17.41400M -11.22100M 668.63M -21.13800M
Net income applicable to common shares -32.90000M -17.41400M -11.22100M 668.63M -21.13800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 227.24M 246.10M 275.18M 353.74M 816.88M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.76M 0.60M 9.89M 84.40M 1.67M
Total liab 8.40M 5.70M 5.79M 5.11M 61.25M
Total stockholder equity 218.85M 240.40M 269.38M 348.64M 755.63M
Deferred long term liab - - - - -
Other current liab 3.58M 1.66M 1.38M 1.49M 53.54M
Common stock 271.15M 267.32M 262.26M 249.81M 324.81M
Capital stock 271.15M 267.32M 262.26M 249.81M 324.81M
Retained earnings -52.30600M -27.74900M 5.15M 97.57M 430.93M
Other liab - 1.64M 2.34M 1.12M 1.06M
Good will - - - - -
Other assets - - -0.00100M 0.53M 75.44M
Cash 200.02M 157.31M 236.98M 237.37M 714.59M
Cash and equivalents - - - - -
Total current liabilities 6.10M 4.07M 3.45M 3.98M 60.19M
Current deferred revenue - - - - 4.50M
Net debt -200.02300M -157.30600M -236.98300M -237.36600M -714.59400M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - 0.83M 1.97M 1.27M -0.10600M
Property plant equipment - 26.26M 28.31M 27.34M 25.17M
Total current assets 201.72M 219.84M 246.87M 325.88M 716.26M
Long term investments - - - - -
Net tangible assets - 240.40M 269.38M 348.64M 755.63M
Short term investments 0.00000M 60.17M - - -
Net receivables 0.94M 1.76M 8.95M 10.69M -
Long term debt - - - - -
Inventory - - -8.95300M -6.57400M -
Accounts payable 2.52M 2.41M 2.07M 2.49M 2.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M 0.83M 1.97M 1.27M -0.10600M
Additional paid in capital - - - - -
Common stock total equity - 267.32M 262.26M 249.81M 324.81M
Preferred stock total equity - - - - -
Retained earnings total equity - -27.74900M 5.15M 97.57M 430.93M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 75.00M
Deferred long term asset charges - - - - -
Non current assets total 25.52M 26.26M 28.31M 27.87M 100.61M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -63.30700M -3.52500M -3.72700M 674.80M -0.12200M
Change to liabilities 0.74M -0.27900M -4.83400M 53.80M 0.15M
Total cashflows from investing activities -63.89200M -3.52500M -3.72700M 674.80M -0.12200M
Net borrowings - - - - -
Total cash from financing activities 0.00000M -67.00800M -409.72400M 42.10M 0.20M
Change to operating activities -0.65300M 76.91M -53.20100M 51.77M 0.59M
Net income -32.90000M -17.41400M -11.22100M 668.63M -21.13800M
Change in cash -79.67700M -0.38300M -477.22800M 698.77M -15.94500M
Begin period cash flow 236.98M 237.37M 714.59M 15.82M 31.77M
End period cash flow 157.31M 236.98M 237.37M 714.59M 15.82M
Total cash from operating activities -14.82400M 69.44M -65.14900M -18.27000M -16.53700M
Issuance of capital stock - 0.00000M - - -
Depreciation 2.61M 2.65M 2.24M 2.36M 2.43M
Other cashflows from investing activities - - - 675.00M -
Dividends paid 0.00000M -75.00300M 75.00M 75.00M 75.00M
Change to inventory - -2.49700M -57.53500M - -
Change to account receivables 0.00000M 4.11M -4.11300M -4.11300M -4.11300M
Sale purchase of stock - 8.00M -409.72400M 41.79M 0.20M
Other cashflows from financing activities -63.89200M 428.00M 10.28M 4.03M -0.12200M
Change to netincome 7.86M 4.46M 12.49M 2.91M 1.66M
Capital expenditures 0.58M 3.52M 3.73M 0.20M 0.12M
Change receivables -1.21600M 4.11M -4.11300M - -
Cash flows other operating 8.07M 75.91M -12.22700M -745.97500M 0.36M
Exchange rate changes - - - 0.15M 0.51M
Cash and cash equivalents changes -78.71600M -1.08800M -478.60000M 698.77M -15.94500M
Change in working capital 7.60M 79.75M -68.74700M -17.61800M 0.51M
Stock based compensation 5.06M 4.46M 12.58M 3.36M 1.66M
Other non cash items 3.62M 0.09M 0.09M -674.55600M 16.98M
Free cash flow -15.40900M 65.92M -68.87600M -18.47400M -16.65900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
XBIT
XBiotech Inc		 - -% 2.37 - - 12.23 1.29 24.05 -2.2743
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

XBiotech Inc

5217 Winnebago Lane, Austin, TX, United States, 78744

Key Executives

Name Title Year Born
Mr. John Simard Founder, Pres, CEO & Chairman 1962
Ms. Queena Han B.A., C.G.A., CPA, CPA VP of Fin. & HR and Sec. 1967
Dr. Sushma Shivaswamy Ph.D. Chief Scientific Officer 1978
Mr. Benjamín Guzmán Sr. VP of Corp. Strategy & Fin. 1956
Ms. Lisa Simard Director of Corp. Strategy - XBiotech USA, Inc. NA
Mr. John Simard Founder, President, CEO & Chairman 1962
Ms. Angela Hu Director of Finance, Principal Financial & Accounting Officer and Financial Controller 1984

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions